Kyung-Don Kang

Kyung-Don Kang

Auto-generated profile, based on publicly available information

Kyung-Don Kang

Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama. 7

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Cancer Discovery
Verified
Journal Article
Closed access
XZXu Zhang
Xu Zhang
SDShoufu Duan
Shoufu Duan
PAPanagiota E. Apostolou
Panagiota E. Apostolou
XWXiaoping Wu
Xiaoping Wu
JWJun Watanabe
Jun Watanabe
ZZZhiguo Zhang
Zhiguo Zhang
High-grade gliomas (HGG) are deadly diseases for both adult and pediatric patients. Recently, it has been shown that neuronal activity promotes the progression of multiple subgroups of HGG. However, epigenetic mechanisms that govern this process remain elusive. Here we report that the chromatin remodeler chromodomain helicase DNA-binding protein 2 (CHD2) regulates neuron–glioma interactions in diffuse midline glioma (DMG) characterized by onco-histone H3.1K27M. Depletion of CHD2 in H3.1K27M DMG cells compromises cell viability and neuron-to-glioma synaptic connections in vitro, neuron-induced proliferation of H3.1K27M DMG cells in vitro and in vivo, activity-dependent calcium transients in vivo, and extends the survival of H3.1K27M DMG-bearing mice. Mechanistically, CHD2 coordinates with the transcription factor FOSL1 to control the expression of axon-guidance and synaptic genes in H3.1K27M DMG cells. Together, our study reveals a mechanism whereby CHD2 controls the intrinsic gene program of the H3.1K27M DMG subtype, which in turn regulates the tumor growth-promoting interactions of glioma cells with neurons. Significance: Neurons drive the proliferation and invasion of glioma cells. Here we show that chromatin remodeler chromodomain helicase DNA-binding protein 2 controls the epigenome and expression of axon-guidance and synaptic genes, thereby promoting neuron-induced proliferation of H3.1K27M diffuse midline glioma and the pathogenesis of this deadly disease.

13 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KKKyung-Don Kang
Kyung-Don Kang
JBJoshua Bernstock
Joshua Bernstock
STStacie Totsch
Stacie Totsch
SGSam E. Gary
Sam E. Gary
ARAbbey Rocco
Abbey Rocco
GFGregory Friedman
Gregory Friedman
Purpose: Oncolytic virotherapy with herpes simplex virus-1 (HSV) has shown promise for the treatment of pediatric and adult brain tumors; however, completed and ongoing clinical trials have utilized intratumoral/peritumoral oncolytic HSV (oHSV) inoculation due to intraventricular/intrathecal toxicity concerns. Intratumoral delivery requires an invasive neurosurgical procedure, limits repeat injections, and precludes direct targeting of metastatic and leptomeningeal disease. To address these limitations, we determined causes of toxicity from intraventricular oHSV and established methods for mitigating toxicity to treat disseminated brain tumors in mice. Experimental Design: HSV-sensitive CBA/J mice received intraventricular vehicle, inactivated oHSV, or treatment doses (1×107 plaque-forming units) of oHSV, and toxicity was assessed by weight loss and IHC. Protective strategies to reduce oHSV toxicity, including intraventricular low-dose oHSV or interferon inducer polyinosinic-polycytidylic acid (poly I:C) prior to oHSV treatment dose, were evaluated and then utilized to assess intraventricular oHSV treatment of multiple models of disseminated CNS disease. Results: A standard treatment dose of intraventricular oHSV damaged ependymal cells via virus replication and induction of CD8+ T cells, whereas vehicle or inactivated virus resulted in no toxicity. Subsequent doses of intraventricular oHSV caused little additional toxicity. Interferon induction with phosphorylation of eukaryotic initiation factor-2α (eIF2α) via intraventricular pretreatment with low-dose oHSV or poly I:C mitigated ependyma toxicity. This approach enabled the safe delivery of multiple treatment doses of clinically relevant oHSV G207 and prolonged survival in disseminated brain tumor models. Conclusions: Toxicity from intraventricular oHSV can be mitigated, resulting in therapeutic benefit. These data support the clinical translation of intraventricular G207.

6 May 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
STStacie Totsch
Stacie Totsch
AIAndrew S. Ishizuka
Andrew S. Ishizuka
KKKyung-Don Kang
Kyung-Don Kang
SGSam E. Gary
Sam E. Gary
ARAbbey Rocco
Abbey Rocco
GFGregory Friedman
Gregory Friedman
Oncolytic virotherapy or immunovirotherapy is a strategy that utilizes viruses to selectively infect and kill tumor cells while also stimulating an immune response against the tumor. Early clinical trials in both pediatric and adult patients using oncolytic herpes simplex viruses (oHSV) have demonstrated safety and promising efficacy; however, combinatorial strategies designed to enhance oncolysis while also promoting durable T-cell responses for sustaining disease remission are likely required. We hypothesized that combining the direct tumor cell killing and innate immune stimulation by oHSV with a vaccine that promotes T cell–mediated immunity may lead to more durable tumor regression. To this end, we investigated the preclinical efficacy and potential synergy of combining oHSV with a self-assembling nanoparticle vaccine codelivering peptide antigens and Toll-like receptor 7 and 8 agonists (referred to as SNAPvax),which induces robust tumor-specific T-cell immunity. We then assessed how timing of the treatments (i.e., vaccine before or after oHSV) impacts T-cell responses, viral replication, and preclinical efficacy. The sequence of treatments was critical, as survival was significantly enhanced when the SNAPvax vaccine was given prior to oHSV. Increased clinical efficacy was associated with reduced tumor volume and increases in virus replication and tumor antigen–specific CD8+ T cells. These findings substantiate the criticality of combination immunotherapy timing and provide preclinical support for combining SNAPvax with oHSV as a promising treatment approach for both pediatric and adult tumors.

5 January 2024 in Translational Oncology
Verified
Journal Article
Open access
ETEric M. Thompson
Eric M. Thompson
KKKyung-Don Kang
Kyung-Don Kang
KSKevin Stevenson
Kevin Stevenson
HZHengshan Zhang
Hengshan Zhang
MGMatthias Gromeier
Matthias Gromeier
GFGregory K. Friedman
Gregory K. Friedman
HSV G207, a double-stranded, DNA virus, and the polio:rhinovirus chimera, PVSRIPO, a single positive-strand RNA virus, are viral immunotherapies being used to treat pediatric malignant brain tumors in clinical trials. The purpose of this work is to elucidate general response patterns and putative biomarkers of response. Multiple pediatric high-grade glioma and medulloblastoma cell lines were treated with various multiplicities of infection of G207 or PVSRIPO. There was a significant inverse correlation between expression of one HSV cellular receptor, CD111, and the lethal dose of 50% of cells (LD50) of cells treated with G207 (r = -0.985, P<0.001) but no correlation between PVSRIPO cellular receptor expression (CD155) and LD50. RNA sequencing of control cells and cells treated for 8 and 24 h revealed that there were few shared differentially expressed (DE) genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched whilst ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and high-grade glioma cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1. Treatment with G207 and PVSRIPO appear to cause disparate gene enrichment and depletion suggesting disparate molecular mechanisms in malignant pediatric brain tumors.

25 November 2025
Verified
Other
Open access
KKKyung-Don Kang
Kyung-Don Kang
JBJoshua Bernstock
Joshua Bernstock
STStacie Totsch
Stacie Totsch
SGSam E. Gary
Sam E. Gary
ARAbbey Rocco
Abbey Rocco
GFGregory Friedman
Gregory Friedman
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.

17 June 2026
Verified
Other
Open access
XZXu Zhang
Xu Zhang
SDShoufu Duan
Shoufu Duan
PAPanagiota E. Apostolou
Panagiota E. Apostolou
XWXiaoping Wu
Xiaoping Wu
JWJun Watanabe
Jun Watanabe
ZZZhiguo Zhang
Zhiguo Zhang
Analysis for DEGs of CHD2-depleted H3.1K27M DMG cells.